Breast Cancer; HER2-positive; Metastatic
Oncology·MeSH: Breast Neoplasms
Prevalence
287.0 / 100K
Incidence
128.0 / 100K/yr
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Breast Cancer; HER2-positive; Metastatic?
BioSniper tracks 2 drugs in development for Breast Cancer; HER2-positive; Metastatic across 1 company.
How many clinical trials target Breast Cancer; HER2-positive; Metastatic?
There are 1 clinical trial targeting Breast Cancer; HER2-positive; Metastatic tracked by BioSniper.
What is the prevalence of Breast Cancer; HER2-positive; Metastatic?
The estimated prevalence of Breast Cancer; HER2-positive; Metastatic is approximately 287.0 per 100,000 population.
Deep-dive into Breast Cancer; HER2-positive; Metastatic
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis